News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Legal AI Conference Lands in L.A. June 17 — Live and Virtual
Masters AI Legal and Cat Casey's TechnoCat partner for a full-day program on practical AI fluency for lawyers. Registration open for in-person and remote attendance.
Ramp hits $44B valuation in Series F, now a unicorn among fintech startups
Ramp closed a Series F funding round at $44 billion valuation, joining a shrinking class of privately-held AI-native enterprise finance platforms. What this means for the spend management market.
Boxabl lands 203-unit order from Texas developer
Boxabl secured its first Phase 2 order: 203 prefab housing units from Shelton Development in Texas. What this signals about modular housing adoption in tight markets.
Neurovia AI Named Official Cybersecurity Partner at Government Summit
Robo.ai subsidiary Neurovia AI will participate as an official government AI cybersecurity partner at the 3rd Government Cybersecurity Summit. Details on the scope of involvement and specific deliverables remain unclear from the announcement.
Merck's Keytruda Combo Beats Chemo in Head-Neck Cancer; Sacituzumab ADC Wins in Endometrial
At ASCO 2026, Merck reported two phase II/III wins: pembrolizumab plus radiotherapy hit 84% two-year PFS in HPV+ head-neck cancer (vs 70% for cisplatin), and sacituzumab tirumotecan met OS and PFS endpoints in post-platinum endometrial cancer. What this means for Keytruda's post-exclusivity pipeline.
Biogen's SMA Drug Wins FDA Breakthrough for Once-Yearly Dosing
Salanersen (BIIB115) earned FDA breakthrough designation based on Phase Ib data showing motor function gains in children who failed gene therapy. Three Phase III trials now underway.
Pfizer Licenses Chai-3 AI Model for Drug Discovery
Pfizer gains early access to Chai Discovery's Chai-3 model, which doubled antibody design success rates. The deal signals pharma's shift toward generative AI for accelerating biologics discovery.
ASCO 2026: Oncology analysts name the readouts that moved the market
GlobalData oncology analysts Jack Cuthbertson and Selena Yu walk through their top clinical readouts from ASCO 2026, including standouts in ADCs, cancer vaccines, and bispecific antibodies.
Parabilis raises $475M to take zolucatetide to Phase III trials
Regeneron-backed biotech Parabilis plans to spend $150M of IPO proceeds on a registrational trial for its β-catenin inhibitor in desmoid tumours, competing directly with SpringWorks' approved Ogsiveo.
Joachim Eeckhout built Labiotech from a bike tour. Now he's plotting what comes next
Episode 200 marks Labiotech's milestone: a founder reflects on building Europe's largest biotech media platform, the acquisition by IN-PART in 2021, and where science communication heads next.
Stipple Bio and Lonza Partner on Tumor-Specific Antibody Cancer Drugs
Stipple Bio licensed Lonza's antibody conjugation and linker technology to develop ADC cancer therapies that target tumor cells while sparing healthy tissue. The deal includes milestone payments and royalties.
MIT Lab Adds Mucosal Immunity to Injectable Polio Vaccine
Researchers paired an experimental adjuvant with the injectable polio vaccine to trigger gut-level immunity in rats, potentially closing a transmission gap that oral vaccines fill but carry safety risks.